Screener
CRISPR Therapeutics CRSP Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Equity-based compensation | 16,324 | 20,212 |
| Other non-cash items, net | 8,800 | 2,253 |
| Changes in: | ||
| Accounts receivable | — | 25,000 |
| Prepaid expenses and other assets | (247) | (634) |
| Accounts payable and accrued expenses | (13,015) | 42,998 |
| Deferred revenue | (427) | (824) |
| Operating lease assets and liabilities | (1,521) | (1,151) |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's accounts receivable?
- CRISPR Therapeutics (CRSP) reported accounts receivable of -$0 in Q1 2026.
- What is the long-term trend for CRISPR Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $144K to $0.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about CRISPR Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude